Retrovirus vectors displaying the IgG-binding domain of protein A

Biochemical and Molecular Medicine

Volumn 62, Issue 1, 1997, Pages 123-127

  Ohno, Kouichi ^a   Meruelo, Daniel ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; VIRUS VECTOR;

ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; BINDING SITE; ENVELOPE GENE; GENE FUSION; GENE TARGETING; MOLONEY MURINE SARCOMA ONCOVIRUS; NONHUMAN; PROTEIN DOMAIN; RETROVIRUS; VIRUS PARTICLE;

MOLONEY MURINE LEUKEMIA VIRUS; MOLONEY MURINE SARCOMA VIRUS; MURINAE; MURINE SARCOMA ONCOVIRUS; ONCOVIRINAE; UNIDENTIFIED RETROVIRUS;

EID: 0031259169     PISSN: 10773150     EISSN: None     Source Type: Journal    
DOI: 10.1006/bmme.1997.2611     Document Type: Article

References (13)

1. 1. Russell SJ, Hawkins RE, Winter G. Retroviral vectors displaying functional antibody fragments. Nucleic Acids Res 21:1081-1085, 1993.
2. 2. Somia NV, Zoppé M, Verma IM. Generation of targeted retroviral vectors by using single-chain variable fragment: An approach to in vivo gene delivery. Proc Natl Acad Sci USA 92:7570-7574, 1995.
3. 3. Marin M, Noël D, Valsesia-Wittman S, Brockly F, Etienne-Julan M, Russel S, Cosset F-L, Piechaczyk M. Targeted infection of human cells via major histocompatibility complex class I molecules by moloney murine leukemia virus-derived viruses displaying single-chain antibody fragment-envelope fusion proteins. J Virol 70:2957-2962, 1996.
4. 4. Kasahara N, Dozy AM, Kan YW. Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. Science 266:1373-1376, 1994.
5. 5. Surolia A, Pain D, Khan MI. Protein A: Nature's universal anti-antibody. Trends Biochem Sci 7:74-76, 1982.
6. 6. Nilsson B, Moks T, Jansson B, Abrahmsén L, Elmblad A, Holmgren E, Henrichson C, Jones TA, Uhlén M. A synthetic IgG-binding domain based on staphylococcal protein A. Protein Eng 1:107-113, 1987.
7. 7. Landau NR, Littman DR. Packaging system for rapid production of murine leukemia virus vectors with variable tropism. J Virol 66:5110-5113, 1992.
8. 8. Löwenadler B, Jansson B, Paleus S, Holmgren E, Nilsson B, Moks T, Palm G, Josephson S, Philipson L, Uhlén M. A gene fusion system for generating antibodies against short peptides. Gene 58:87-97, 1987.
9. 9. Mann R, Mulligan RC, Baltimore D. Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell 33:153-159, 1983.
10. 10. Han X, Kasahara N, Kan YW. Ligand-directed retroviral targeting of human breast cancer cells. Proc Natl Acad Sci USA 92:9747-9751, 1995.
11. 11. Etienne-Julan M, Roux P, Carillo S, Jeanteur P, Piechaczyk M. The efficiency of cells targeting by recombinant retroviruses depends on the nature of the receptor and the composition of the artificial cell-virus linker. J Gen Virol 73:3251-3255, 1992.
12. 12. Roux P, Jeanteur P, Piechaczyk M. A versatile and potentially general approach to the targeting of specific cell types by retrovirus: Application to infection of human cells by means of major histocompatibility complex class I and class II antigens by mouse ecotropic murine leukemia virus-derived viruses. Proc Natl Acad Sci USA 86: 1989.
13. 13. Ohno K, Sawai K, Iijima Y, Levin B, Meruelo D. Cell-specific targeting of Sindbis virus vectors displaying IgG-binding domain of protein A. Nat. Biotechnol., in press, 1997.